*Tema mítico* : ⚡⚡(HILO OFICIAL) : CRISIS DEL cobi19 ☣SARS-CoV2☣

JgarmA dijo:
shishi, hoy hay un optimismo desmesurado en las bolsas y en el ambiente. Parece que los datos mejoran. Curioso cuanto menos. Al final todos esos que decían que esto estaba muy ligado a las elecciones de EUA puede que no estén muy desencaminados.
Hacer clic para expandir...
Desde luego el timing esta siendo bastante curioso... luego que si hay magufos... :D
 
Quien facilita los datos a los científicos ? costa y sus palmeros?

"concluye que las bases de datos del Sistema Nacional de Vigilancia Epidemiológica (SINAVE) que se han proporcionado a la comunidad científica en los últimos meses, sobre los casos el bichito-19, tienen baja calidad, errores, inconsistencias y mucha información faltante."
 
Primer aviso de Bruselas a Pedro Sánchez: España saldrá del bichito con el doble de déficit de la Eurozona loser:

1604926278561.png


Primer aviso de Bruselas a Sánchez: España saldrá del bichito con el doble de déficit de la Eurozona
 
BNT_logo.jpg




After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.


“Today is a great day for science and humanity. The first set of results from our Phase 3 el bichito-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent el bichito-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”


“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.”


“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent el bichito-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed el bichito-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.”


The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed el bichito-19 cases have accrued. The study also will evaluate the potential for the vaccine candidate to provide protection against el bichito-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe el bichito-19 disease. In addition to the primary efficacy endpoints evaluating confirmed el bichito-19 cases accruing from 7 days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well. The companies believe that the addition of these secondary endpoints will help align data across all el bichito-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms. The companies have posted an updated version of the study protocol

Pfizer and BioNTech are continuing to accumulate safety data and currently estimate that a median of two months of safety data ***owing the second (and final) dose of the vaccine candidate – the amount of safety data specified by the FDA in its guidance for potential Emergency Use Authorization – will be available by the third week of November. Additionally, participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.


Along with the efficacy data generated from the clinical trial, Pfizer and BioNTech are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced.


Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.


Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most antiestéticared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.


Salu2
 
Última edición:
De DR ( deplorable recollector ) rumano

Tasa de infección por bichito CHINO FUERA de China; ACTUALIZAR Página 302
¿Ni siquiera a los globalistas les gusta "una buena cena y un espectáculo"? En otras palabras, ¿REALMENTE se benefician tanto para que el mundo se convierta en Full Mad Max? Parece contraproducente dado lo mucho que ya controlan de todos modos.
Citando: Trisherella


No se benefician de un escenario de Mad Max.


Pero se benefician de la anarquía y la ley marcial.


El riesgo es perder el control de lo que QUIEREN que suceda, de lo que EVITAN que suceda.


CHINESE bichito infection rate OUTSIDE China; UPDATE Page 302

Don't even globalists like, "a nice dinner and a show?" In other words, do they REALLY benefit all that much for the world to go Full Mad Max? Seems self-defeating given how much they already control anyway.
Quoting: Trisherella

They don't benefit form a mad max scenario.


But they do benefit from anarchy and martial law.


The risk is losing control of what they WANT to happen, for what they AVOID to happen.
 
Última edición:
- Creo que no se está gestionando bien la esa época en el 2020 de la que yo le hablo en España
- Eso es delito
- ¿Lo de la gestión?
- No, decirlo, como se entere Iván Redondo vas al talego. sonrisa:
 
Iniciar sesión o registrarte para responder aquí.
Volver